Abstract
Objectives-To identify clinical, electrophysiological, and immunological characteristics of chronic immune demyelinating polyneuropathy to define for each group the appropriate therapeutic strategies. Methods-The clinical and electrophysiological data and the response to treatment of 93 patients with an acquired chronic dysimmune demyelinating polyneuropathy (CDDP) studied over a period of 10 years were reviewed. Two groups were identified: group 1, comprising 64 patients with an idiopathic CDDP, of whom 13 had serum monoclonal or polyclonal gammopathy without detectable antibodies directed against the "myelin associated glycoprotein" (MAG), and group 2, comprising 29 The patient's clinical disability was graded according to the following criteria: (1) mild motor or sensory symptoms and signs; (2) moderate motor or sensory involvement; (3) severe involvement requiring assistance for eating, dressing, or walking.
ELECTRODIAGNOSTIC EXAMINATIONS
Needle EMG examination was performed in all patients. Although the recruitment pattern, amplitude, form, and duration of motor unit potentials were evaluated, we used only the presence or absence of fibrillation potentials. A motor nerve conduction study of the median, ulnar, and peroneal nerves was performed. Compound muscle action potential (CMAP) amplitudes, conduction velocities, distal latencies, F wave latencies, and proximal/distal amplitude ratios were reviewed. A conduction block was defined as a reduction of more than 50% of the proximal:distal amplitude ratio at Erb's point and more than 30% elsewhere. However, a reduction of the CMAP amplitude was considered to be due to temporal dispersion if the duration of CMAP was 15% greater after proximal stimulation when compared with the distal CMAP. A minimum of 10 consecutive distal F waves were elicited for each nerve, and the minimal F wave latency was measured. Median, ulnar, sural, and superficial peroneal sensory nerve action potentials were recorded, and peak to peak amplitude and conduction velocity were measured. The terminal latency index (TLI; distal conduction distance in mm/proximal conduction velocity in m/s/distal motor latency in ms) was used to compare distal and proximal segment conduction velocity.'625 Distal conduction distances, between the recording electrode over the motor point and the site of distal nerve stimulation, were 60 mm for the median and ulnar nerves and 90 mm for the peroneal nerve.
The electrophysiological criteria defined by the American Academy of Neurology ad hoc subcommittee26 for the diagnosis of chronic demyelinating polyneuropathies were applied and evaluated in our patients.
LABORATORY STUDIES
All patients were studied with serum immunoelectrophoresis. Malignant plasma cell dyscrasia was ruled out by bone marrow examination and radiological skeletal study. Anti-MAG activity was studied by immunoblotting in all patients with IgM MGUS. When more than one CSF examination was performed the results of the initial study were retained. disclosed a demyelinating process (table 2) . Temporal dispersion of the CMAP or conduction block were present in one or more motor nerves in 89% of patients. F waves were absent or their minimal latency was often increased. Fibrillation potentials or positive sharp waves were found in 23% of patients (table 3) .
Terminal latency index was determined in 181 normal subjects (controls) for the median nerve (0-34 (SD 0 04)), ulnar nerve (0-43 (SD 0 07)), and peroneal nerve (0 48 (SD 0 07)). In CDDP, mean TLI did not differ significantly from controls, but there was considerable heterogeneity. Three patterns were found: (1) low TLI values (distal conduction was very much more reduced in comparison to proximal conduction); (2) values comparable with those of controls (distal conduction identical to proximal conduction); (3) high values (proximal conduction lower than distal conduction).
Biological study Examination of CSF was performed in 51 patients (79%), most of whom were found to have high protein concentrations: 94-1% in relapsing CDDP (mean = 1 18 (SD 0 89) g/l) and 90 9% in progressive CDDP (mean = 1-06 (SD 0 57) g/l). All CSF analyses disclosed a normal cell count.
In group 1, 12 patients had IgM MGUS without anti-MAG activity, one had IgG MGUS, four had a polyclonal gammopathy, of whom three had IgM and one IgG. The other 47 patients had normal immunoelectrophoresis results. Nine patients initially had no evidence of a monoclonal gammopathy but subsequently developed a MGUS. The mean delay was four years (range seven months to nine years); in four of nine patients, the gammopathy was initially polyclonal over a period of many months or several years. In these patients, malignant plasma cell dyscrasias were exluded by radiological skeletal surveys and by haematological evaluations, which included a bone marrow examination. There were no differences in presentation, initial clinical course, or initial electrodiagnostic features which could be used to distinguish patients with CDDP with delayed MGUS from the other patients with CDDP.
The follow up study showed that three patients had subsequently developed associated systemic conditions in addition to CDDP (none at the time of diagnosis): one chronic active hepatitis, one non-Hodgkin's malignant lymphoma, and one solid cancer (ovarian). These occurred two, six, and four years, respectively, after the polyneuropathy was diagnosed. These patients could not be distinguished from the other patients with CDDP, either clinically or electrophysiologically or in terms of the subsequent course of the neuropathy.
Treatment and evolution Forty patients (68-5%) were treated. In those with the progressive form, the initial treatment was oral prednisone (60 mg/day) in 89-6% of patients. Most of the patients (93%) experienced no improvement or only marginal improvement with initial treatment. Three received secondary treatment with azathioprine, two with cyclophosphamide, four with cyclosporine and 13 with intravenous IVIg. A favourable response occurred in only 41-8% of treated patients. In the relapsing form, 15 of 19 (79%) patients were treated: seven with prednisone alone and four with additional plasma exchanges. Four patients received IVIg. Improvement after treatment occurred in 86&6%. Twenty patients were not treated (23-5%): four with relapsing CDDP and 16 with progressive CDDP. Of those not treated, 10 improved spontaneously, four were stable, and eight worsened. Neither age, clinical course, MNCV, CMAP, nor CSF protein concentration were predictive of the clinical outcome. Only the presence of conduction block and the correspondence of electrophysiological criteria with that of the ad hoc subcommittee26 showed a significant correlation with a favourable clinical course.
Comparison ofprogressive and relapsing CDDP Mean age at onset was significantly lower in patients with relapsing CDDP compared with the progressive form (41-3 (SD 16-4) v 51-2 (SD 18-6) years). The clinical presentation was not significantly different, but none of the patients had predominant sensory neuropathy; cranial nerve involvement was more frequent in the relapsing subgroup than in the progressive subgroup (36-9% v 17-8%). In the relapsing subgroup, proximal weakness was also more frequent. Impairment of overall function was similar. In the relapsing subgroup, motor nerve distal conduction was more severely affected (table 4) and temporal dispersion occurred more often (P = 0031). Patients with relapsing CDDP therefore fulfilled more closely the electrophysiological criteria of the ad hoc subcommittee26 (P = 0043). The relapsing patients were more responsive to treatment, especially by corticosteroids.
GROUP 2 PATIENTS
Clinical presentation was mainly sensory. A generalised areflexia was found in nearly two thirds of the patients. The course was usually progressive without subacute onset. No clinical CNS involvement was found.
Distal motor latencies seemed to be disproportionately increased for the degree of proxi- mal conduction slowing, as reflected by the lower TLI. The mean TLI was significantly lower than mean values in controls for the median, ulnar, and peroneal nerves (P = 0o0001; table 2). Conduction blocks were rare and sensory potentials were always altered (table 3) . The CSF was examined in 22 patients (75 8%). All had a raised protein concentration with a mean of 1 11 (SD 0 44) g/l (range 05 to 2 g/l). Cell count was normal.
Twenty eight (96 5%) patients were treated. The most common initial treatment was chlorambucil (23 patients The sensitivity of the electrodiagnostic criteria of the ad hoc subcommittee26 allowed the recognition of 79-3% of group 2 patients and 71-8% of group 1 patients. In group 1, the criteria were met by 89-5% of relapsing CDDP cases (the difference was significant for the progressive CDDP subgroup; P = 0-04).
Discussion
Chronic acquired demyelinating polyneuropathies are usually classified as chronic inflammatory demyelinating polyradiculoneuropathy (CIDP), multifocal demyelinating neuropathy with persistent conduction block, and paraproteinaemic demyelinating polyneu- Sixty four patients had CIDP without anti-MAG activity. There was a slight male predominance, in accordance with other studies.'3202228 Age at onset was identical to that found in the study by Barohn et al20 but higher than that found by McCombe et al. 22 The difference was probably due to our recruitment of adult patients only. The clinical features were similar to those reported previously. '5 2I022 28 Patients (15 5%) with only sensory symptoms were included. They presented a large alteration in motor nerve conduction velocity with conduction block despite an absence of motor deficit. The pure sensory form has been considered as a different entity,20 30 19 We have shown that patients with chronic demyelinating polyneuropathy and anti-MAG antibody differ significantly from other patients with this type of polyneuropathy but without anti-MAG antibodies. Anti-MAG antibodies act, probably with a specific mechanism, on the nerve fibre, and may be related to the level of anti-MAG antibodies, as recently suggested. 18 In our experience, results of treatment also differ between groups 1 and 2. In the group of patients without anti-MAG activity (group 1), progressive patients were more resistant to steroids than relapsing patients. Azathioprine 
